

ROCKWELL MEDICAL, INC.

TRANSFORMING IRON DEFICIENCY AND ANEMIA MANAGEMENT

Q1 2021 Financial Results and Business Update

May 17, 2021

FORWARD-LOOKING STATEMENTS

Certain statements in this presentation may constitute "forward-looking statements" within the meaning of federal securities laws, including, but not limited to, the market opportunity for home infusion, the benefits, safety and efficacy of FPC, the cost of clinical development of FPC for home infusion, the market opportunity for home infusion and the timing of anticipated milestones, including data readouts, regulatory decisions and commercial launch. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "can," "could," "would," "develop," "plan," "potential," "predict," "forecast," "project," "plan", "intend" or the negatives of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this presentation. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: the potential impact of COVID-19 pandemic (including, applicable federal, state and local orders) on business, clinical development plans and operating results, including our supply chain, dialysis concentrates business, the commercial launch of Triferic Dialysate and Triferic AVNU and our anticipated milestones; statements about the challenges inherent in new product development and other indications and therapeutic areas for our products; the likelihood of success and timing of our international development and commercialization plans, including regulatory filings and clinical trials; the success of and our commercialization of Triferic Dialysate domestically and internationally; the success and timing of our commercialization of Triferic AVNU; the expected number of annualized treatments for Triferic Dialysate and Triferic AVNU; the risk that regulatory authorities delay or fail to approve FPC for new indications; the risk that market opportunities are smaller than estimated; the risk that Rockwell Medical is not able to seek reimbursement for FPC for new indications; the risk that FPC is unsafe for new indications; the risk that clinical study designs, timing and costs are different than estimated; expected financial performance, including cash flows, revenues, growth, margins, funding, liquidity and capital resources; and those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2020, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

Triferic® is a registered trademark of Rockwell Medical, Inc. Triferic AVNU is pending with the U.S. Patent and Trademark Office. All other product names, logos, and brands are property of their respective owners in the United States and/or other countries. All company, product and service names used on this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement.

CEO REMARKS

Home infusion is rapidly growing & iron deficiency is a problem.

Home infusion is a large and expanding area of healthcare.¹

3.2

million patients
treated annually

400%

growth from
2010 - 2019

Iron deficiency anemia is a common comorbidity.
Treatment paradigm is a broken process.²



FPC may be uniquely suited to address the problem and improve lives.



The market opportunity is significant.



The clinical development pathway is relatively low risk and low cost.



The safety and efficacy of FPC has already been established in dialysis patients.

We believe FPC is **uniquely suited** to address the crisis of iron deficiency anemia in home infusion patients.

Limitations of current treatment options...

Risk of hypersensitivity reactions with IV iron.

Inflammation and hepcidin block of iron in the liver.


Inconsistent loading doses of IV iron.



ferric pyrophosphate citrate (FPC)



Safety profile similar to placebo.^{1,2}



100% immediately bioavailable iron, bypassing storage in the liver.³

Fe³⁺

Bioavailable even in the presence of inflammation and elevated hepcidin.




Regular, low doses at home could treat and prevent recurrence of iron deficiency anemia.³

1. Fishbane SN, Singh AK, Cournoyer SH, et al. Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. *Nephrol Dial Transplant.* 2015;30(12):2019-2026.
2. Gupta A, Lin V, Guss C, Pratt R, Ikizler A, Besarab A. Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis stimulating agent use and maintains hemoglobin in hemodialysis patients. *Kidney Int.* 2015;88(5):1187-1194.
3. TRIFERIC Prescribing Information. Wixom, MI: Rockwell Medical, Inc.; 2018.

Home infusion growth driven by multiple trends

Home Infusion Therapy Patients Served¹



- Aging population
- Cost and risk of in-person care
- COVID-19 pandemic
- Robust pipeline for specialty drugs
- Favorable reimbursement
- New technology
- Patient preferred

1. NHIA Infusion Industry Trends Report 2020.

Home infusion patient populations are at risk of iron deficiency anemia, which may expand the market for FPC.


Therapy	total # of patients ¹	Estimated % iron deficient / FPC eligible
Home parenteral nutrition	113,000	~50% ²
Hydration therapy	160,000	at increased risk
Inotropes	86,000	~50% ^{4,6}
Chemotherapy	111,000	~17% ³
Anti-infectives	1,400,000	at increased risk
Biologics	160,000	~10% ⁵

Estimated Total U.S. Market Opportunity
up to \$600M⁷

1. NHIA Infusion Industry Trends Report 2020.
 2. Hwa YL, Rashtak S, Kelly DG, and Murray JA. Iron deficiency in long-term parenteral nutrition therapy. JPEN 2015.
 3. Busti E, et al. Anemia and iron deficiency in cancer patients. Role of iron replacement therapy. Pharmaceuticals 2018, 11, 94.

4. Beale A, et al. Iron Deficiency in Acute Decompensated Heart Failure. J. Clin. Med. 2019, 8, 1569.
 5. Kaitha S, et al. Iron deficiency anemia in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2015. 6(3):62-72.
 6. von Haehling S, et al. Iron Deficiency in Heart Failure. JACC. 2019. 7(1):36-46.
 7. This estimate is based upon Rockwell's current estimated patient count, dose administration and pricing

Our expected near-term milestones.



8 * All estimates are based upon clinical trial being waived and subject to potential delays related to COVID-19 pandemic within India
 ** Request for clinical trial waiver has been filed, but Technical Committee adjudication has been delayed due to COVID-19.
 *** Chile and Peru

We are investing to drive growth in the short, mid, and long term.

Commercialized Products in Dialysis

- Dialysis Concentrates
- Triferic[®]
- Triferic AVNU[®]
- Global Expansion

Home Infusion Opportunity

- FPC for treatment of iron deficiency anemia
- Phase II expected to start 2H 2021

Development Pipeline

- Additional therapies from our FPC platform
Acute heart failure, others

Leveraging our platform technology



ferric pyrophosphate citrate (FPC)

THANK YOU

 **ROCKWELL**
MEDICAL

 **ROCKWELL**
MEDICAL